Ongericimab

Phase 2Monoclonal antibody

SShanghai Junshi Bioscience Co., Ltd.

Ongericimab is one of 12 biologic programs targeting Advanced Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Colorectal CancerRecruiting

Advanced Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Advanced Colorectal Cancer

#DrugCompanyPhaseTrials

Erbitux

IImclone

Phase 3

2 2

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Phase 2

1 3

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 4

MRTX849

MMirati Therapeutics Inc.

Phase 3

1 5

Defactinib

VVerastem, Inc.

Phase 2

1 6

Eloxatin

Teva

Preclinical

1 7

Avastin

Roche

Preclinical

1 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 9

5-Fluorouracil

Merck & Co.

Preclinical

1 10

Ongericimab

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Advanced Colorectal Cancer

NCT07106034

Clinical

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT05325203·135 enrolled

Advanced Colorectal Cancer1 trial

Clinical Study of Second-Line Standard Therapy Combined With Ongericimab and Toripalimab in Patients With MSS/pMMR Colorectal Cancer Following First-Line Treatment Failure

Recruiting·SShanghai Pudong Hospital·Phase 2·NCT07106034·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ongericimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ongericimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ongericimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

Ongericimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

Advanced Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News